Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

[News]

Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

More... (http://www.news-medical.net/news/20150506/Acacia-Pharma-reports-positive-results-from-APD403-Phase-2-study-in-CINV.aspx)